Biote Corp

BTMD has transitioned into a confirmed Stage 2 advance after breaking above multi-month resistance, but with price extended above rising EMAs and 50 DMA into extreme overbought, we will wait for a constructive pullback into the 9 EMA, 21 EMA, and 50 DMA support zone before adding exposure, consistent with our Free Cash Flow + Buybacks strategy and mindful that failure to hold these levels would undermine the medium-term bullish structure.

• ↑FY26 revenue guidance above $190M indicates procedural recovery post-recall
• ↑Dietary supplement revenue up 30% YoY to $11M, driven by e-commerce
• ↓Q1 revenue fell 8.3% YoY to $44.9M, with procedure rev down 13.2%